Perphenazine - PharmaKB

Perphenazine

Perphenazine (perphenazine) is a small molecule pharmaceutical. Perphenazine was first approved as Triavil 2-25 on 1982-01-01. It is used to treat huntington disease, nausea, psychotic disorders, reye syndrome, and schizophrenia amongst others in the USA. The pharmaceutical is active against D(2) dopamine receptor. In addition, it is known to target 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2C, histamine H1 receptor, 5-hydroxytryptamine receptor 7, and 5-hydroxytryptamine receptor 6.

Download report

Favorite

Events Timeline

Commercial

Clinical

Drug

Target

Variants

Financial

Trends

Safety

Events Timeline

YTD

Max

Events

FDA approval date

EMA approval date

Patent expiration date

Study first post date

Last update post date

Start date

Primary completion date

Completion date

Results first post date

Mock data
Subscribe for the real data

Commercial

Therapeutic Areas

Therapeutic Area	MeSH
digestive system diseases	D004066
nervous system diseases	D009422
hereditary congenital and neonatal diseases and abnormalities	D009358
nutritional and metabolic diseases	D009750
signs and symptoms pathological conditions	D013568
chemically-induced disorders	D064419
mental disorders	D001523

Trade Name

FDA

EMA

Perphenazine (discontinued: Perphenazine, Trilafon)

Combinations

Perphenazine amitriptyline (discontinued: Etrafon, Perphenazine amitriptyline, Triavil)

Drug Products

FDA

EMA

New Drug Application (NDA)

Abbreviated New Drug Application (ANDA)

Amitriptyline hydrochloride

Perphenazine

Tradename	Company	Number	Date	Products
TRIAVIL 2-25	New River Pharmaceuticals	N-014715 DISCN	1982-01-01	1 products
TRIAVIL 4-10	New River Pharmaceuticals	N-014715 DISCN	1982-01-01	1 products
TRIAVIL 2-10	New River Pharmaceuticals	N-014715 DISCN	1982-01-01	1 products
TRIAVIL 4-25	New River Pharmaceuticals	N-014715 DISCN	1982-01-01	1 products
TRIAVIL 4-50	New River Pharmaceuticals	N-014715 DISCN	1982-01-01	1 products
ETRAFON-A	Merck & Co	N-014713 DISCN	1982-01-01	1 products
ETRAFON 2-25	Merck & Co	N-014713 DISCN	1982-01-01	1 products
ETRAFON-FORTE	Merck & Co	N-014713 DISCN	1982-01-01	1 products
ETRAFON 2-10	Merck & Co	N-014713 DISCN	1982-01-01	1 products

Hide discontinued

Perphenazine

Tradename	Company	Number	Date	Products
TRILAFON	Merck & Co	N-010775 DISCN	1982-01-01	4 products, RLD
TRILAFON	Merck & Co	N-011213 DISCN	1982-01-01	1 products
TRILAFON	Merck & Co	N-011294 DISCN	1982-01-01	1 products
TRILAFON	Merck & Co	N-011361 DISCN	1982-01-01	1 products
TRILAFON	Merck & Co	N-011557 DISCN	1982-01-01	1 products

Hide discontinued

Labels

FDA

EMA

Brand Name	Status	Last Update
perphenazine	ANDA	2024-11-05
perphenazine and amitriptyline hydrochloride	ANDA	2024-10-31

Indications

FDA

EMA

Indication	Ontology	MeSH	ICD-10
substance withdrawal syndrome	EFO_0005800	D013375	—
pain	EFO_0003843	D010146	R52
vomiting	HP_0002013	D014839	R11.1
nausea	HP_0002018	D009325	R11.0
torticollis	HP_0000473	D014103	F45.8
tourette syndrome	EFO_0004895	D005879	F95.2
huntington disease	Orphanet_399	D006816	G10
schizophrenia	EFO_0000692	D012559	F20
psychotic disorders	—	D011618	F20.81
psychotic affective disorders	—	D000341	F39

Show 2 more

Agency Specific

FDA

EMA

No data

Patent Expiration

No data

ATC Codes

N: Nervous system drugs

— N05: Psycholeptics

— N05A: Antipsychotics

— N05AB: Phenothiazines with piperazine structure, antipsychotics

— N05AB03: Perphenazine

HCPCS

Code	Description
J3310	Injection, perphenazine, up to 5 mg
Q0175	Perphenazine, 4 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen

Clinical

Clinical Trials

176 clinical trials

View more details

Mock data
Subscribe for the real data

Indications Phases 4

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Migraine disorders	D008881	EFO_0003821	G43	1	2	5	4	7	19
Schizophrenia	D012559	EFO_0000692	F20	—	2	2	8	6	18
Headache	D006261	HP_0002315	R51	—	2	4	2	6	14
Depression	D003863	—	F33.9	3	1	3	3	4	14
Myofascial pain syndromes	D009209	EFO_1001054	—	1	5	4	3	3	13
Fibromyalgia	D005356	EFO_0005687	M79.1	1	4	3	3	3	12
Pain	D010146	EFO_0003843	R52	—	4	6	3	2	12
Neuralgia	D009437	EFO_0009430	—	1	3	4	3	—	11
Psychotic disorders	D011618	—	F20.81	—	1	2	4	2	9
Depressive disorder	D003866	EFO_1002014	F32.A	1	1	2	2	2	8

Show 38 more

Indications Phases 3

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Peripheral nervous system diseases	D010523	HP_0009830	G64	—	8	6	—	1	11
Neoplasms	D009369	—	C80	—	—	3	—	—	3
Tension-type headache	D018781	HP_0012228	G44.2	—	—	1	—	2	3
Interstitial cystitis	D018856	EFO_1000869	N30.1	—	—	2	—	1	3
Vomiting	D014839	HP_0002013	R11.1	—	—	1	—	1	2
Dementia	D003704	EFO_0003862	F03	—	—	2	—	—	2
Multiple myeloma	D009101	—	C90.0	—	1	1	—	—	2
Plasma cell neoplasms	D054219	—	—	—	1	1	—	—	2
Neurotoxicity syndromes	D020258	—	G92	—	—	2	—	—	2
Musculoskeletal pain	D059352	—	—	—	—	2	—	—	2

Show 32 more

Indications Phases 2

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Healthy volunteers/patients	—	—	—	7	1	—	—	2	9
Intervertebral disc displacement	D007405	EFO_1001800	—	—	1	—	—	2	3
Hiv infections	D015658	EFO_0000764	B20	—	1	—	—	1	2
Nervous system diseases	D009422	—	G00-G99	—	1	—	—	1	2
Cocaine-related disorders	D019970	—	F14	1	2	—	—	—	2
Pruritus	D011537	HP_0000989	L29	—	1	—	—	1	2
Fibrosis	D005355	—	—	—	2	—	—	—	2
Cystic fibrosis	D003550	EFO_0000390	E84	—	2	—	—	—	2
Infections	D007239	EFO_0000544	—	—	2	—	—	—	2
Breast neoplasms	D001943	EFO_0003869	C50	—	1	—	—	—	1

Show 30 more

Indications Phases 1

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Drug interactions	D004347	—	—	1	—	—	—	1	2
Obesity	D009765	EFO_0001073	E66.9	1	—	—	—	—	1
Body weight	D001835	EFO_0004338	—	1	—	—	—	—	1
Enuresis	D004775	—	R32	1	—	—	—	—	1
Neuritis	D009443	—	—	1	—	—	—	—	1

Indications Without Phase

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Radiculopathy	D011843	—	M54.1	—	—	—	—	3	3
Taste disorders	D013651	—	—	—	—	—	—	3	3
Drug-related side effects and adverse reactions	D064420	—	T88.7	—	—	—	—	2	2
Bipolar disorder	D001714	EFO_0000289	F30.9	—	—	—	—	2	2
Hernia	D006547	HP_0100790	K40-K46	—	—	—	—	2	2
Arthritis	D001168	HP_0001369	M05-M14	—	—	—	—	1	1
Tendinopathy	D052256	EFO_1001434	M77.9	—	—	—	—	1	1
Synovitis	D013585	EFO_0008997	M67.5	—	—	—	—	1	1
Spasm	D013035	—	M62.83	—	—	—	—	1	1
Gout	D006073	EFO_0004274	M10	—	—	—	—	1	1

Show 12 more

Epidemiology

Epidemiological information for investigational and approved indications

View more details

Drug

General

Drug common name	Perphenazine
INN	perphenazine
Description	Perphenazine is a phenothiazine derivative in which the phenothiazine tricycle carries a chloro substituent at the 2-position and a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at N-10. It has a role as a phenothiazine antipsychotic drug, a dopaminergic antagonist and an antiemetic. It is a member of phenothiazines, a N-alkylpiperazine, a N-(2-hydroxyethyl)piperazine and an organochlorine compound. It derives from a hydride of a 10H-phenothiazine.
Classification	Small molecule
Drug class	Typical antipsychotic
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)	OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1

Identifiers

PDB	—
CAS-ID	58-39-9
RxCUI	—
ChEMBL ID	CHEMBL567
ChEBI ID	8028
PubChem CID	4748
DrugBank	DB00850
UNII ID	FTA7XXY4EZ (ChemIDplus, GSRS)

Target

Agency Approved

DRD2

Organism

Homo sapiens

Gene name

DRD2

Gene synonyms

NCBI Gene ID

1813

Protein name

D(2) dopamine receptor

Protein synonyms

Dopamine D2 receptor, seven transmembrane helix receptor

Uniprot ID

Q9UPA9

Mouse ortholog

Drd2 (13489)

D(2) dopamine receptor (Q0VGH9)

Alternate

HTR2A

HTR2C

HRH1

HTR7

HTR6

Organism

Homo sapiens

Gene name

HTR2A

Gene synonyms

HTR2

NCBI Gene ID

3356

Protein name

5-hydroxytryptamine receptor 2A

Protein synonyms

5-HT2 receptor, 5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled, serotonin 5-HT-2A receptor, Serotonin receptor 2A

Uniprot ID

Q5T8C0

Mouse ortholog

Htr2a (15558)

5-hydroxytryptamine receptor 2A (P35363)

Variants

No data

Financial

Revenue by drug

€

₣

No data

Estimated US medical usage

Perphenazine

Amitriptyline

Total medical expenditures per year (USD, in millions)

Mock data
Subscribe for the real data

Number of persons purchased

Mock data
Subscribe for the real data

Number of purchases

Mock data
Subscribe for the real data

Refill frequency

Mock data
Subscribe for the real data

Price per prescription (USD)

Mock data
Subscribe for the real data

Perphenazine

Total medical expenditures per year (USD, in millions)

Mock data
Subscribe for the real data

Number of persons purchased

Mock data
Subscribe for the real data

Number of purchases

Mock data
Subscribe for the real data

Refill frequency

Mock data
Subscribe for the real data

Price per prescription (USD)

Mock data
Subscribe for the real data

Tabular view

Trends

PubMed Central

Top Terms for Disease or Syndrome:

Mock data
Subscribe for the real data

Additional graphs summarizing 3,475 documents

View more details

Safety

Black-box Warning

Black-box warning for: Perphenazine, Perphenazine and amitriptyline hydrochloride

Adverse Events

Top Adverse Reactions

Mock data
Subscribe for the real data

1,519 adverse events reported

View more details